OsteoConnections

Thanks for visiting the official website and blog of the University Health Network and Mount Sinai Hospital Osteoporosis Program.

Osteoporosis is a major public health concern, with over 2 million Canadians currently suffering from the disease. This figure is expected to rise to 6.9 million by the end of the year.

Our clinic, led by Dr. Angela M. Cheung, provides diagnostic and clinical services to osteoporosis patients and people with low bone mass (referral). Every year, over 3000 patients walk through our clinic doors! We also have a dynamic research programme that is led by expert physicians and researchers in the field.

Please feel free to browse our website to learn more about osteoporosis, the research we conduct, and important tips for better bone health!

Recent Posts

Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy

A Propensity Score–Matched Cohort Study Abstract Background: An osteoporosis drug holiday is recommended for most patients after 3 to 5 years of therapy. Risedronate has a shorter half-life than alendronate, and thus the residual length of fracture protection may be shorter. Objective: To examine the comparative risks of drug holidays after long-term (≥3 years) risedronate … Continue reading Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy

COVID-19 VACCINATION AND OSTEOPOROSIS DRUG THERAPY

Dr. Aliya Khan, Dr. Heather Frame, Dr. Claudia Gagnon, Dr. Rowena Ridout, Dr. Lianne Tile and Dr. Sandra Kim Recommendations from Osteoporosis Canada Rapid Response Team Osteoporosis is a chronic condition which requires consistent pharmacologic intervention. There is currently no evidence that osteoporosis therapy increases the risk or the severity of COVID-19 infections. With the … Continue reading COVID-19 VACCINATION AND OSTEOPOROSIS DRUG THERAPY

More Posts